SETDB1 and neoplasm: Co-administration of CDK4/6 inhibitor palbociclib obviously enhanced the therapeutic efficacy of SETDB1 depletion on tumor growth by protecting TRIM28-mediated p-RB from proteasomal degradation both in vitro and in vivo [103].